keyword
MENU ▼
Read by QxMD icon Read
search

Testosterone replacement therapy

keyword
https://www.readbyqxmd.com/read/28078224/impact-of-recent-fda-ruling-on-testosterone-replacement-therapy-trt
#1
Sarita O Metzger, Arthur L Burnett
No abstract text is available yet for this article.
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078222/testosterone-replacement-therapy-and-the-heart-friend-foe-or-bystander
#2
REVIEW
David S Lopez, Steven Canfield, Run Wang
The role of testosterone therapy (TTh) in cardiovascular disease (CVD) outcomes is still controversial, and it seems will remain inconclusive for the moment. An extensive body of literature has investigated the association of endogenous testosterone and use of TTh with CVD events including several meta-analyses. In some instances, a number of studies reported beneficial effects of TTh on CVD events and in other instances the body of literature reported detrimental effects or no effects at all. Yet, no review article has scrutinized this body of literature using the magnitude of associations and statistical significance reported from this relationship...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078221/testosterone-replacement-therapy-and-voiding-dysfunction
#3
REVIEW
Wesley Baas, Tobias S Köhler
Testosterone replacement therapy (TRT) represents an increasing popular treatment option for men with late-onset hypogonadism (LOH). Because of unsubstantiated beliefs of testosterone's effect on the prostate, the FDA has recently placed a warning on testosterone products, stating that TRT may worsen benign prostatic hyperplasia (BPH). Within this review article we have demonstrated the current understanding of the physiology of testosterone and its relationship with prostatic and lower urinary tract physiology...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078220/hypogonadism-and-testosterone-replacement-therapy-in-end-stage-renal-disease-esrd-and-transplant-patients
#4
REVIEW
Grace Snyder, Daniel A Shoskes
Hypogonadism is a common problem in the end-stage renal disease (ESRD) and renal transplant population. It has widespread systemic effects and has been linked with mortality in dialysis patients and at the time of renal transplant. The etiology is likely multifactorial and most patients are afflicted by various comorbidities that can contribute to hypogonadism. Clinical manifestations are mostly nonspecific. We review the approach to the diagnosis of hypogonadism, focusing on both laboratory values and clinical signs and symptoms...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078216/testosterone-replacement-therapy-role-of-pituitary-and-thyroid-in-diagnosis-and-treatment
#5
REVIEW
Megan Crawford, Laurence Kennedy
Crosstalk among hormones characterizes endocrine function, and assessment of the hypogonadal man should take that into consideration. In men for whom testosterone deficiency is a concern, initial evaluation should include a thorough history and physical exam in which other endocrinopathies are being considered. Hypogonadism can be associated with both pituitary and thyroid dysfunction, for which appropriate biochemical evaluation should be undertaken in certain clinical scenarios. If low serum testosterone is confirmed measurement of luteinizing and follicle stimulating hormones (LH and FSH respectively) is essential to establish whether the hypogonadism is primary or secondary...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078215/off-label-therapies-for-testosterone-replacement
#6
REVIEW
Lorenzo DiGiorgio, Hossein Sadeghi-Nejad
The incidence of hypogonadism has been steadily increasing over the last few years. Exogenous testosterone has been the standard treatment for hypogonadal men, but is associated with suppression of spermatogenesis as well as other possible adverse effects. There are other medications, currently considered "off label" for androgen replenishment, that exert their effect through modulation of the hypothalamic-gonadal axis. These medications increase endogenous testosterone levels and offer a different therapeutic approach...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078214/pharmacology-of-testosterone-replacement-therapy-preparations
#7
REVIEW
Jennifer J Shoskes, Meghan K Wilson, Michael L Spinner
The goal of testosterone replacement therapy (TRT) is to return serum testosterone levels to within physiologic range and improve symptoms in hypogonadal men. Some of the symptoms aimed to improve upon include decreased libido, erectile dysfunction, infertility, hot flashes, depressed mood, and loss of muscle mass or hair. Clinical use of testosterone for replacement therapy began approximately 70 years ago. Over the decades, numerous preparations and formulations have been developed primarily focusing on different routes of delivery and thus pharmacokinetics (PKs)...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078213/adult-onset-hypogonadism-evaluation-and-role-of-testosterone-replacement-therapy
#8
REVIEW
Andrew J Davidiuk, Gregory A Broderick
Testosterone deficiency (TD) has become a growing concern in the field of men's sexual health, with an increasing number of men presenting for evaluation of this condition. Given the increasing demand for testosterone replacement therapy (TRT), a panel of experts met in August of 2015 to discuss the treatment of men who present for evaluation in the setting of low or normal gonadotropin levels and the associated signs and symptoms of hypogonadism. This constellation of factors can be associated with elements of both primary and secondary hypogonadism...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078212/improvement-of-endothelial-function-following-initiation-of-testosterone-replacement-therapy
#9
Daniel A Shoskes, Barbara Tucky, Allan S Polackwich
BACKGROUND: Isolated recent studies have suggested an increased risk of heart attack as early as 3 months following testosterone replacement therapy (TRT). Such a rapid risk increase would likely require rapid deterioration of arterial endothelial function. Our goal was to assess arterial endothelial function in hypogonadal men prior to and at least 3 months after initiation of TRT. METHODS: Adult men were consented if they had symptoms of hypogonadism, a total testosterone <350 ng/dL, and planned to begin TRT...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078211/a-case-series-of-the-safety-and-efficacy-of-testosterone-replacement-therapy-in-renal-failure-and-kidney-transplant-patients
#10
Ahmad Majzoub, Daniel A Shoskes
BACKGROUND: Hypogonadism is common in patients with renal dysfunction and does not always correct following transplantation. Recent studies show increased mortality for dialysis and transplant patients with low testosterone (T). These patients are often not treated due to concerns over efficacy and complications (both real and imagined). There is surprisingly scant literature supporting the use of T therapy in these patients. We wished to examine the results of T therapy in our patients with renal failure or following transplant...
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28078210/testosterone-replacement-therapy
#11
Daniel A Shoskes, Lawrence S Hakim
No abstract text is available yet for this article.
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28053953/letter-to-the-editor-regarding-treatment-of-men-for-low-testosterone-a-systematic-review-by-huo-et-al-testosterone-replacement-therapy-toward-to-the-robust-evidence-and-facts
#12
COMMENT
Jae Hung Jung, Sang-Kuk Yang
No abstract text is available yet for this article.
December 2016: World Journal of Men's Health
https://www.readbyqxmd.com/read/28053949/effect-of-testosterone-replacement-therapy-on-cognitive-performance-and-depression-in-men-with-testosterone-deficiency-syndrome
#13
Hyun Jin Jung, Hong Seok Shin
PURPOSE: We aimed to evaluate the effect of testosterone replacement therapy (TRT) on cognitive function and depression in men with testosterone deficiency syndrome. MATERIALS AND METHODS: We carried out a prospective, placebo-controlled trial involving 106 men with total testosterone levels <3.3 ng/mL and symptoms of hypogonadism. Based on whether the patients received TRT (injection with 1,000 mg testosterone undecanoate) or a placebo (advice to modify lifestyle), the study population was divided into a TRT group (n=54) and a control group (n=52)...
December 2016: World Journal of Men's Health
https://www.readbyqxmd.com/read/28024968/assessing-the-variability-in-insurance-coverage-transparency-for-male-sexual-health-conditions-in-the-united-states
#14
Brian V Le, Sarah McAchran, David Paolone, Daniel R Gralneck, Daniel Williams, Wade Bushman
OBJECTIVES: To determine the degree of transparency of health insurer policies regarding coverage of male sexual health conditions, we examined the publicly available policy coverage documents of the largest US medical insurance plans. METHODS: We selected two index patients across the male sexual health spectrum: (1) a PDE5 refractory erectile dysfunction patient requiring intracavernosal injection therapy or penile prosthesis, (2) a 50 yo male patient with laboratory-confirmed, symptomatic hypogonadism requiring testosterone replacement therapy as defined by endocrine society criteria...
December 23, 2016: Urology
https://www.readbyqxmd.com/read/27998231/hypothalamic-pituitary-axis-dysfunction-in-survivors-of-childhood-cns-tumors-importance-of-systematic-follow-up-and-early-endocrine-consultation
#15
Wassim Chemaitilly, Gregory T Armstrong, Amar Gajjar, Melissa M Hudson
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
December 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27997352/transdermal-testosterone-gel-for-induction-and-continuation-of-puberty-in-adolescent-boys-with-hepatic-dysfunction
#16
Maria F Contreras, Manish Raisingani, Kris Prasad, Bonita Franklin, Bina Shah
Treatment to induce puberty in boys is indicated in those who do not undergo spontaneous development at a normal age. Stimulating development of the secondary sex characteristics is possible using gradually increasing doses of testosterone esters (TEs) via intramuscular (IM) administration, which is the most widely used method of testosterone (T) supplementation. When TEs are administered as monthly injection, serum T levels exhibit large fluctuations with supraphysiologic levels seen immediately after the injection followed by a decrease into the low range...
January 1, 2017: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/27992261/effects-of-testosterone-replacement-on-electrocardiographic-parameters-in-men-findings-from-two-randomized-trials
#17
Thiago Gagliano-Jucá, Tevhide Betül İçli, Karol M Pencina, Zhuoying Li, John Tapper, Grace Huang, Thomas G Travison, Panayiotis Tsitouras, S Mitchell Harman, Thomas W Storer, Shalender Bhasin, Shehzad Basaria
CONTEXT: Endogenous testosterone levels have been negatively associated with QTc interval in small case series; the effects of testosterone therapy on electrocardiographic parameters have not been evaluated in randomized trials. OBJECTIVE: To evaluate the effects of testosterone replacement on corrected QT interval (QTcF) in two randomized controlled trials. PARTICIPANTS: Men with pre- and post-randomization electrocardiograms (ECGs) from the Testosterone and Pain (TAP) and the Testosterone Effects on Atherosclerosis in Aging Men (TEAAM) Trials...
December 19, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27984109/a-comparison-of-secondary-polycythemia-in-hypogonadal-men%C3%A2-treated-with-clomiphene-citrate-versus-testosterone-replacement-a-multi-institutional-study
#18
Karen M Wheeler, Ryan P Smith, Raj A Kumar, Shaan Setia, Raymond A Costabile, Parviz K Kavoussi
PURPOSE: We evaluated the relative prevalence of secondary polycythemia in hypogonadal men treated with clomiphene citrate or testosterone replacement therapy. MATERIALS AND METHODS: In this retrospective, multi-institutional study, we included 188 men who received clomiphene citrate and 175 who received testosterone replacement therapy with symptomatic hypogonadism. The overall prevalence and ORs of secondary polycythemia for clomiphene citrate treatment vs testosterone replacement were primarily measured, as were baseline characteristics...
October 27, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27982202/a-boy-with-prader-willi-syndrome-unmasking-precocious-puberty-during-growth-hormone-replacement-therapy
#19
Natasha G Ludwig, Rafael F Radaeli, Mariana M X Silva, Camila M Romero, Alexandre J F Carrilho, Danielle Bessa, Delanie B Macedo, Maria L Oliveira, Ana Claudia Latronico, Tânia L Mazzuco
Prader-Willi syndrome (PWS) is a genetic disorder frequently characterized by obesity, growth hormone deficiency, genital abnormalities, and hypogonadotropic hypogonadism. Incomplete or delayed pubertal development as well as premature adrenarche are usually found in PWS, whereas central precocious puberty (CPP) is very rare. This study aimed to report the clinical and biochemical follow-up of a PWS boy with CPP and to discuss the management of pubertal growth. By the age of 6, he had obesity, short stature, and many clinical criteria of PWS diagnosis, which was confirmed by DNA methylation test...
November 2016: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27981728/physicians-response-to-sexual-dysfunction-presented-by-a-younger-vs-an-older-adult
#20
Ateret Gewirtz-Meydan, Liat Ayalon
AIM: The aim of this study is to determine whether physicians have an age bias regarding sexual dysfunction presented by older vs. younger patients in terms of attributed diagnosis, etiology, proposed treatment and perceived prognosis. METHOD: An on-line survey consisting of one of two, randomly administered, case vignettes, which differed only by the age of the patient (28 or 78). In both cases, the patient was described as suffering from occasional erectile dysfunction with a clear psychosocial indication...
December 16, 2016: International Journal of Geriatric Psychiatry
keyword
keyword
25535
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"